Literature DB >> 32543726

GABAergic dysfunction in excitatory and inhibitory (E/I) imbalance drives the pathogenesis of Alzheimer's disease.

Danlei Bi1,2,3, Lang Wen1,2,3, Zujun Wu1,2,3, Yong Shen1,2,3.   

Abstract

OBJECTIVE: To propose a new hypothesis that GABAergic dysfunction in excitatory and inhibitory (E/I) imbalance drives the pathogenesis of Alzheimer's disease (AD).
BACKGROUND: Synaptic dysfunction and E/I imbalance emerge decades before the appearance of cognitive decline in AD patients, which contribute to neurodegeneration. Initially, E/I imbalance was thought to occur first, due to dysfunction of the glutamatergic and cholinergic systems. However, new evidence has demonstrated that the GABAergic system, the counterpart of E/I balance and the major inhibitory neurotransmitter system in the central nervous system, is altered enormously and that this contributes to E/I imbalance and further AD pathogenesis. NEW HYPOTHESIS: Alterations to the GABAergic system, induced by multiple AD pathogenic or risk factors, contribute to E/I imbalance and AD pathogenesis. MAJOR CHALLENGES FOR THE HYPOTHESIS: This GABAergic hypothesis accounts for many critical questions and common challenges confronting a new hypothesis of AD pathogenesis. More specifically, it explains why amyloid beta (Aβ), β-secretase (BACE1), apolipoprotein E4 gene (APOE ε4), hyperactive glia cells, contributes to AD pathogenesis and why age and sex are the risk factors of AD. GABAergic dysfunction promotes the spread of Aβ pathology throughout the AD brain and associated cognitive impairments, and the induction of dysfunction induced by these varied risk factors shares this common neurobiology leading to E/I imbalance. In turn, some of these factors exacerbate GABAergic dysfunction and E/I imbalance. Moreover, the GABAergic system modulates various brain functions and thus, the GABAergic hypothesis accounts for nonamnestic manifestations. Furthermore, corrections of E/I balance through manipulation of GABAergic functions have shown positive outcomes in preclinical and clinical studies, suggesting the potential of the GABAergic system as a therapeutic target in AD. LINKAGE TO OTHER MAJOR THEORIES: Dysfunction of the GABAergic system is induced by multiple critical signaling pathways, which include the existing major theories of AD pathogenesis, such as the Aβ and neuroinflammation hypotheses. In a new perspective, this GABAergic hypothesis accounts for the E/I imbalance and related excitotoxicity, which contribute to cognitive decline and AD pathogenesis. Therefore, the GABAergic system could be a key target to restore, at least partially, the E/I balance and cognitive function in AD patients.
© 2020 the Alzheimer's Association.

Entities:  

Keywords:  Alzheimer's disease; E/I balance; GABA; GABA receptor; GABAergic neuron; amyloid β peptide

Year:  2020        PMID: 32543726     DOI: 10.1002/alz.12088

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  15 in total

1.  Safrole oxide induced 5-HT neuron-like cell differentiation of bone marrow mesenchymal stem cells by elevating G9a.

Authors:  Xianjing Han; Yanchun Zhao; Chunhui Sun; Kunlun Li; Baoxiang Zhao; Junying Miao; Le Su
Journal:  In Vitro Cell Dev Biol Anim       Date:  2022-08-01       Impact factor: 2.723

Review 2.  Neurotransmitters-Key Factors in Neurological and Neurodegenerative Disorders of the Central Nervous System.

Authors:  Raluca Ioana Teleanu; Adelina-Gabriela Niculescu; Eugenia Roza; Oana Vladâcenco; Alexandru Mihai Grumezescu; Daniel Mihai Teleanu
Journal:  Int J Mol Sci       Date:  2022-05-25       Impact factor: 6.208

Review 3.  The Yin and Yang of GABAergic and Glutamatergic Synaptic Plasticity: Opposites in Balance by Crosstalking Mechanisms.

Authors:  Caitlyn A Chapman; Jessica L Nuwer; Tija C Jacob
Journal:  Front Synaptic Neurosci       Date:  2022-05-19

4.  Increased Hippocampal Excitability and Altered Learning Dynamics Mediate Cognitive Mapping Deficits in Human Aging.

Authors:  Nadine Diersch; Jose P Valdes-Herrera; Claus Tempelmann; Thomas Wolbers
Journal:  J Neurosci       Date:  2021-03-01       Impact factor: 6.167

5.  Synaptic dysregulation and hyperexcitability induced by intracellular amyloid beta oligomers.

Authors:  Eduardo J Fernandez-Perez; Braulio Muñoz; Denisse A Bascuñan; Christian Peters; Nicolas O Riffo-Lepe; Maria P Espinoza; Peter J Morgan; Caroline Filippi; Romain Bourboulou; Urmi Sengupta; Rakez Kayed; Jérôme Epsztein; Luis G Aguayo
Journal:  Aging Cell       Date:  2021-08-19       Impact factor: 9.304

6.  Neurotransmitter-stimulated neuron-derived sEVs have opposite effects on amyloid β-induced neuronal damage.

Authors:  Yunxiao Dou; Junchao Xie; Yan Tan; Min Zhang; Yanxin Zhao; Xueyuan Liu
Journal:  J Nanobiotechnology       Date:  2021-10-15       Impact factor: 10.435

7.  Microglia regulate chandelier cell axo-axonic synaptogenesis.

Authors:  Nicholas B Gallo; Artan Berisha; Linda Van Aelst
Journal:  Proc Natl Acad Sci U S A       Date:  2022-03-09       Impact factor: 12.779

8.  Neuronal C/EBPβ/AEP pathway shortens life span via selective GABAnergic neuronal degeneration by FOXO repression.

Authors:  Yiyuan Xia; Hiroshi Qadota; Zhi-Hao Wang; Pai Liu; Xia Liu; Karen X Ye; Courtney J Matheny; Ken Berglund; Shan Ping Yu; Derek Drake; David A Bennett; Xiao-Chuan Wang; Bruce A Yankner; Guy M Benian; Keqiang Ye
Journal:  Sci Adv       Date:  2022-03-30       Impact factor: 14.957

9.  Anti-Epileptic Effects of FABP3 Ligand MF1 through the Benzodiazepine Recognition Site of the GABAA Receptor.

Authors:  Yasushi Yabuki; Jiaqi Liu; Ichiro Kawahata; Hisanao Izumi; Yasuharu Shinoda; Kohei Koga; Shinya Ueno; Norifumi Shioda; Kohji Fukunaga
Journal:  Int J Mol Sci       Date:  2020-08-01       Impact factor: 5.923

10.  Impaired Expression of GABA Signaling Components in the Alzheimer's Disease Middle Temporal Gyrus.

Authors:  Karan Govindpani; Clinton Turner; Henry J Waldvogel; Richard L M Faull; Andrea Kwakowsky
Journal:  Int J Mol Sci       Date:  2020-11-18       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.